Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable MedicineBusiness Wire • 10 days ago
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal or the Company) today announced the launch of PEMRYDI RTU, the first and only ready-to-use presentation of pemetrexed for injection. This product...
Share to Feed
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host...
Lauren Clason | (TNS) CQ-Roll Call
A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma...
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal or the Company), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (Amneal or the Company) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA...
This is a signal that AMRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that AMRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that AMRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that AMRX's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...
This is a Bullish indicator signaling AMRX's price could rise from here. Traders may explore going long the stock or buying call options...